TC BioPharm (TCBP) declared a special dividend of 0.25 ADS per ADS held, pending shareholder approval on December 30, 2024. The company, focused on gamma-delta T-cell cancer therapies, is conducting pivotal clinical trials for acute myeloid leukemia (AML) using its CryoTC technology. Despite the dividend announcement, TCBP stock fell 1.94% pre-market.